A randomized trial of 316 women aged 35 and older found that adding growth hormone to IVF protocols did not significantly raise the rate of chromosomally normal blastocysts, researchers reported in Scientific Reports on November 21.
The study, led by Zhang Shunji and colleagues, compared standard ovarian stimulation against stimulation preceded and accompanied by daily subcutaneous growth hormone injections at 2 to 4 international units. The euploid blastocyst rate per patient reached 37.78% in the treatment arm versus 31.55% in controls, a difference of six percentage points that missed statistical significance with a p-value of 0.325, Mondosanità reported. The average number of euploid blastocysts per woman was 0.98 versus 0.89, also not significant.
“The advantage sought has not been demonstrated in these women, with this scheme,” the Mondosanità analysis concluded. The findings reinforce updated guidance from the European Society of Human Reproduction and Embryology (ESHRE), which advises against routine growth hormone use in poor responders, and align with the UK Human Fertilisation and Embryology Authority (HFEA) stance that add-ons must show proven benefit before being offered.
“Time gives weight to the question, not the promise,” the Mondosanità editorial said, urging patients to ask which clinical outcome an add-on improves and with what certainty.
Adding Growth Hormone to IVF for Women over 35 Did Not Increase Normal Embryos
- Adding growth hormone to IVF for women over 35 did not produce a statistically reliable increase in chromosomally normal embryos in this trial.
- The study measured embryo quality (euploidy), not live births; no data yet show the add-on improves the chance of taking home a baby.
- Major European and UK fertility bodies already recommend against routine use of this add-on due to insufficient evidence.
Trial Enrolled 316 Women Aged 35 or Older
The prospective, randomized, controlled trial enrolled 316 women with infertility aged 35 years or older. Participants were randomized to conventional IVF or IVF plus growth hormone administered subcutaneously starting roughly two menstrual cycles before ovarian stimulation and continuing through stimulation. All resulting embryos underwent preimplantation genetic testing for aneuploidy (PGT-A), the primary endpoint being the euploid blastocyst rate per patient.
Euploid blastocysts are embryos at day five or six of development that carry the correct number of chromosomes. Aneuploidy rates rise sharply with maternal age, driving implantation failure and miscarriage. However, the study authors and Mondosanità cautioned that euploidy rates are a surrogate marker; the definitive clinical endpoints — clinical pregnancy and live birth — were not reported as significantly different.
Regulatory Context and Add-On Scrutiny
ESHRE’s 2023 good practice recommendations on ovarian stimulation note that evidence for growth hormone in poor responders remains low quality and inconsistent, advising against its routine use. The HFEA traffic-light system rates growth hormone as “red,” indicating no high-quality evidence of effectiveness and potential safety concerns.
In the United States, the FDA has not approved growth hormone for IVF augmentation; its use remains off-label, and the American Society for Reproductive Medicine (ASRM) considers the evidence insufficient to recommend routine adoption.
Funding details for the Zhang et al. trial were not disclosed in the Mondosanità report or the Scientific Reports abstract. The study was published open access in Scientific Reports on November 21, 2026 (DOI: 10.1038/s41598-026-77929-0), according to Mondosanità.
Founded in 1985 by Robert Edwards of the University of Cambridge and Jean Cohen of Paris, the European Society of Human Reproduction and Embryology (ESHRE) is headquartered in Belgium. Its official journal, Human Reproduction, comprises three publications, including Human Reproduction Update, and the society develops data registries and good practice recommendations that shape clinical standards across Europe.
| Outcome | Growth Hormone + IVF | IVF Alone (Control) | P-value |
|---|---|---|---|
| Euploid blastocyst rate per patient | 37.78% | 31.55% | 0.325 |
| Mean euploid blastocysts per patient | 0.98 | 0.89 | Not significant |
The Zhang Shunji et al. trial, “Effect of growth hormone on euploid blastocyst rate in advanced-age women: a prospective, randomized, controlled trial,” was published November 21, 2026, in Scientific Reports.
References
- Zhang S, Tang Y, Peng Y et al. Effect of growth hormone on euploid blastocyst rate in advanced-age women: a prospective, randomized, controlled trial. Sci Rep. 2026;16:xxxx. doi:10.1038/s41598-026-77929-0.
- European Society of Human Reproduction and Embryology (ESHRE). Good practice recommendations on ovarian stimulation. 2023.
- Human Fertilisation and Embryology Authority (HFEA). Treatment add-ons: growth hormone. Accessed November 2026.
- American Society for Reproductive Medicine (ASRM). Committee opinion on adjuvant therapies in IVF. Fertil Steril. 2022.